The Breast Cancer therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of 12.5% during the forecast period.
China account for 12·2% of all newly diagnosed breast cancers and 9·6% of all deaths from breast cancer worldwide. China’s proportional contribution to global rates is increasing rapidly because of the population’s rising socioeconomic status and unique reproductive patterns. The breast cancer awareness program in china are run by collaboration of private and government organizations. The market focus on early diagnosis and standardized treatments can improve disease outcome and quality of life.
Prolonged exposure to endogenous oestrogens, early menarche, late age at first childbirth and late menopause are the primary factors driving the growth of breast cancer therapeutics market in china. Increased consumption oral birth control pills, use of hormones replacement therapy and increased alcohol consumption rate among women in china is leading to increased levels of oestrogen which will boost the business size over the forecast period. Growing awareness regarding breast cancer and risk factors like adoption of western lifestyle as well as short breast-feeding time frame will drive the growth of the market in china.